Drug delivery to the suprachoroidal space

Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems

Volumn , Issue , 2012, Pages 235-258

  Cho, Sung Won ^a,b   Olsen, Timothy W ^a  

^a EMORY EYE CENTER   (United States)

^b Kim's Eye Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885000921     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12950     Document Type: Chapter

References (122)

1. Adamis, A.P., and D.T. Shima. 2005. The role of vascular endothelial growth factor in ocular health and disease. Retina 25 (2):111-8.
2. Alm, A., and S.F.E. Nilsson. 2009. Uveoscleral outflow-A review. Exp Eye Res 88 (4):760-8.
3. Ambati, J., C.S. Canakis, J.W. Miller, E.S. Gragoudas, A. Edwards, D.J. Weissgold, I. Kim, F.C. Delori, and A.P. Adamis. 2000. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 41 (5):1181-5.
4. Ambati, J., E.S. Gragoudas, J.W. Miller, T.T. You, K. Miyamoto, F.C. Delori, and A.P. Adamis. 2000. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 41 (5):1186-91.
5. Amrite, A.C., H.F. Edelhauser, S.R. Singh, and U.B. Kompella. 2008. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis, 14, 150-60.
6. Amrite, A., V. Pugazhenthi, N. Cheruvu, and U. Kompella. 2010. Delivery of celecoxib for treating diseases of the eye: Influence of pigment and diabetes. Expert Opin Drug Deliv 7 (5):631-45.
7. Anderson, C.R., R.L. Morris, S.D. Boeh, P.C. Panus, and W.L. Sembrowich. 2003. Effects of iontophoresis current magnitude and duration on dexamethasone deposition and local-ized drug retention. Phys Ther 83 (2):161-70.
8. AREDS Group, Age-Related Eye Disease Study Research. 2001. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereo-scopic color fundus photographs: The Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol 132 (5):668-81.
9. Augustin, A.J., and I. Offermann. 2006. Emerging drugs for age-related macular degeneration. Expert Opin Emerg Drugs 11 (4):725-40.
10. Aukunuru, J.V., G. Sunkara, N. Bandi, W.B. Thoreson, and U.B. Kompella. 2001. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm Res 18 (5):565-72.
11. Azeem, A., M.K. Anwer, and S. Talegaonkar. 2009. Niosomes in sustained and targeted drug delivery: Some recent advances. J Drug Target 17 (9):671-89.
12. Balachandran, R.K., and V.H. Barocas. 2008. Computer modeling of drug delivery to the pos-terior eye: Effect of active transport and loss to choroidal blood flow. Pharm Res 25 (11):2685-96.
13. Baltmr, A., J. Duggan, S. Nizari, T.E. Salt, and M.F. Cordeiro. 2010. Neuroprotection in glau-coma-Is there a future role? Exp Eye Res 91 (5):554-66.
14. Barar, J., A.R. Javadzadeh, and Y. Omidi. 2008. Ocular novel drug delivery: Impacts of mem-branes and barriers. Expert Opin Drug Deliv 5 (5):567-81.
15. Barnett, P.J. 2009. Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled release platform). Conf Proc IEEE Eng Med Biol Soc, 2009, 3087-90.
16. Bill, A. 1965. Movement of albumin and dextran through the sclera. Arch Ophthalmol, 74, 248-52.
17. Bill, A., P. Törnquist, and A. Alm. 1980. Permeability of the intraocular blood vessels. Trans Ophthalmol Soc U K 100 (3):332-6.
18. Brar, M., L. Cheng, R. Yuson, F. Mojana, W.R. Freeman, and P.S. Gill. 2010. Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signal-ling. Br J Ophthalmol 94 (12):1668-73.
19. Brown, D.M., P.K. Kaiser, M. Michels, G. Soubrane, J.S. Heier, R.Y. Kim, J.P. Sy, S. Schneider, and ANCHOR Study Group. 2006. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (14):1432-44.
20. Brubaker, R.F. 1982. The flow of aqueous humor in the human eye. Trans Am Ophthalmol Soc, 80, 391-474.
21. BVOS. 1986. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 104 (1):34-41.
22. Cai, X., S.M. Conley, and M.I. Naash. 2010. Gene therapy in the retinal degeneration slow model of retinitis pigmentosa. Adv Exp Med Biol, 664, 611-9.
23. Campbell, R.J., S.E. Bronskill, C.M. Bell, J.M. Paterson, M. Whitehead, and S.S. Gill. 2010. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: A population-based analysis. Arch Ophthalmol 128 (3):359-62.
24. Campochiaro, P.A., G. Hafiz, R. Channa, S.M. Shah, Q.D. Nguyen, H. Ying, D.V. Do et al. 2010. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes. Ophthalmology 117 (12):2387-94.e5.
25. Cheng, L., K.Y. Hostetler, J. Lee, H.J. Koh, J.R. Beadle, K. Bessho, M. Toyoguchi, K. Aldern, J. Bovet, and W.R. Freeman. 2004. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci 45 (11):4138-44.
26. Cheruvu, N.P.S., A.C. Amrite, and U.B. Kompella. 2008. Effect of eye pigmentation on trans-scleral drug delivery. Invest Ophthalmol Vis Sci 49 (1):333-41.
27. Cheruvu, N.P.S., and U.B. Kompella. 2006. Bovine and porcine transscleral solute transport: Influence of lipophilicity and the choroid-Bruch’s layer. Invest Ophthalmol Vis Sci 47 (10):4513-22.
28. Chong, D.Y., M.W. Johnson, T.H. Huynh, E.F. Hall, G.M. Comer, and D.N. Fish. 2009. Vitreous penetration of orally administered famciclovir. Am J Ophthalmol 148 (1):38-42.e1.
29. Cruysberg, L.P.J., R.M.M.A. Nuijts, D.H. Geroski, J.A. Gilbert, F. Hendrikse, and H.F. Edelhauser. 2005. The influence of intraocular pressure on the transscleral diffusion of high-molecular-weight compounds. Invest Ophthalmol Vis Sci 46 (10):3790-4.
30. Cunha-Vaz, J.G., and D.M. Maurice. 1967. The active transport of fluorescein by the retinal vessels and the retina. J Physiol 191 (3):467-86.
31. Davies, N.M. 2000. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 27 (7):558-62.
32. de la Fuente, M., B. Seijo, and M.J. Alonso. 2008. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci 49 (5):2016-24.
33. Del Amo, E.M., and A. Urtti. 2008. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 13 (3-4):135-43.
34. Ding, X.-Q., A.B. Quiambao, J.B. Fitzgerald, M.J. Cooper, S.M. Conley, and M.I. Naash. 2009. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One 4 (10):e7410.
35. DRCR Network, Diabetic Retinopathy Clinical Research Network, R.W. Beck, A.R. Edwards, L.P. Aiello, N.M. Bressler, F. Ferris, A.R. Glassman et al. 2009. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127 (3):245-51.
36. DRCR Network, Diabetic Retinopathy Clinical Research Network, M.J. Elman, L.P. Aiello, R.W. Beck, N.M. Bressler, S.B. Bressler, A.R. Edwards et al. 2010. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117 (6):1064-77.e35.
37. Duvvuri, S., S. Majumdar, and A.K. Mitra. 2003. Drug delivery to the retina: Challenges and opportunities. Expert Opin Biol Ther 3 (1):45-56.
38. Einmahl, S., S. Ponsart, R.A. Bejjani, F. D’Hermies, M. Savoldelli, J. Heller, C. Tabatabay, R. Gurny, and F. Behar-Cohen. 2003. Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. J Biomed Mater Res A 67 (1):44-53.
39. Einmahl, S., M. Savoldelli, F. D’Hermies, C. Tabatabay, R. Gurny, and F. Behar-Cohen. 2002. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci 43 (5):1533-9.
40. Eljarrat-Binstock, E., A.J. Domb, F. Orucov, J. Frucht-Pery, and J. Pe’er. 2007. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res 32 (7-8):639-46.
41. Falkenstein, I.A., L. Cheng, T.R. Jones, W.R. Freeman, B. Babson, I. Kozak, A.M. Tammewar, and E.C. Barron. 2010. Intraocular properties of a repository urokinase receptor antagonist a36 Peptide in rabbits. Curr Eye Res 35 (8):742-50.
42. Friedman, D.S., B.J. O’Colmain, B. Muñoz, S.C. Tomany, C. McCarty, P.T.V.M. de Jong, B. Nemesure, P. Mitchell, J. Kempen, and Eye Diseases Prevalence Research Group. 2004. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 (4):564-72.
43. Fu, Y., M.L. Ponce, M. Thill, P. Yuan, N.S. Wang, and K.G. Csaky. 2007. Angiogenesis inhibi-tion and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci 48 (11):5184-90.
44. Gandhi, M.D., D. Pal, and A.K. Mitra. 2004. Identification and functional characterization of a Na(+)-independent large neutral amino acid transporter (LAT2) on ARPE-19 cells. Int J Pharm 275 (1-2):189-200.
45. Gaudana, R., H.K. Ananthula, A. Parenky, and A.K. Mitra. 2010. Ocular drug delivery. AAPS J 12 (3):348-60.
46. Ghate, D., and H.F. Edelhauser. 2006. Ocular drug delivery. Expert Opin Drug Deliv 3 (2):275-87.
47. Giansanti, F., M. Ramazzotti, L. Vannozzi, E. Rapizzi, T. Fiore, B. Iaccheri, D.D. Innocenti, D. Moncini, and U. Menchini. 2008. A pilot study on ocular safety of intravitreal inflix-imab in a rabbit model. Invest Ophthalmol Vis Sci 49 (3):1151-6.
48. Gilger, B.C., J.H. Salmon, D.A. Wilkie, L.P.J. Cruysberg, J. Kim, M. Hayat, H. Kim et al. 2006. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci 47 (6):2596-605.
49. Gilger, B.C., D.A. Wilkie, A.B. Clode, R.J. McMullen, M.E. Utter, A.M. Komaromy, D.E. Brooks, and J.H. Salmon. 2010. Long-term outcome after implantation of a supracho-roidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet Ophthalmol 13 (5):294-300.
50. Gupta, N., L.-C. Ang, L. Noël de Tilly, L. Bidaisee, and Y.H. Yücel. 2006. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol 90 (6):674-8.
51. Heller, J. 2005. Ocular delivery using poly(ortho esters). Adv Drug Deliv Rev 57 (14):2053-62.
52. Hou, J., Y. Tao, Y.-R. Jiang, and K. Wang. 2009. In vivo and in vitro study of suprachoroidal fibrin glue. Jpn J Ophthalmol 53 (6):640-7.
53. Ip, M.S., N.L. Oden, I.U. Scott, P.C. VanVeldhuisen, B.A. Blodi, M. Figueroa, A. Antoszyk, M. Elman, and SCORE Study Investigator Group. 2009. SCORE Study report 3: Study design and baseline characteristics. Ophthalmology 116 (9):1770-7.e1.
54. Jacobson, S.G., and A.V. Cideciyan. 2010. Treatment possibilities for retinitis pigmentosa. N Engl J Med 363 (17):1669-71.
55. Jaffe, G.J., R.M. McCallum, B. Branchaud, C. Skalak, Z. Butuner, and P. Ashton. 2005. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112 (7):1192-8.
56. Janoria, K.G., S.H.S. Boddu, S. Natesan, and A.K. Mitra. 2010. Vitreal pharmacokinetics of peptide-transporter-targeted prodrugs of ganciclovir in conscious animals. J Ocul Pharmacol Ther 26 (3):265-71.
57. Janoria, K.G., S. Gunda, S.H.S. Boddu, and A.K. Mitra. 2007. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4 (4):371-88.
58. Jiang, J., D.H. Geroski, H.F. Edelhauser, and M.R. Prausnitz. 2006. Measurement and prediction of lateral diffusion within human sclera. Invest Ophthalmol Vis Sci 47 (7):3011-6.
59. Jiang, J., J.S. Moore, H.F. Edelhauser, and M.R. Prausnitz. 2009. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res 26 (2):395-403.
60. Kanamori, A., M.-M. Catrinescu, A. Mahammed, Z. Gross, and L.A. Levin. 2010. Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy. J Neurochem 114 (2):488-98.
61. Kane, F.E., J. Burdan, A. Cutino, and K.E. Green. 2008. Iluvien: A new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 5 (9):1039-46.
62. Kansara, V., Y. Hao, and A.K. Mitra. 2007. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: Targeting the oligopeptide transporter on rabbit retina. J Ocul Pharmacol Ther 23 (4):321-34.
63. Kennedy, B.G., and N.J. Mangini. 2002. P-glycoprotein expression in human retinal pigment epithelium. Mol Vis, 8, 422-30.
64. Kim, E.S., C. Durairaj, R.S. Kadam, S.J. Lee, Y. Mo, D.H. Geroski, U.B. Kompella, and H.F. Edelhauser. 2009. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res 26 (5):1155-61.
65. Kim, H., M.R. Robinson, M.J. Lizak, G. Tansey, R.J. Lutz, P. Yuan, N.S. Wang, and K.G. Csaky. 2004. Controlled drug release from an ocular implant: An evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 45 (8):2722-31.
66. Kim, S.H., C.J. Galbán, R.J. Lutz, R.L. Dedrick, K.G. Csaky, M.J. Lizak, N.S. Wang, G. Tansey, and M.R. Robinson. 2007. Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci 48 (2):808-14.
67. Kim, S.H., R.J. Lutz, N.S. Wang, and M.R. Robinson. 2007. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 39 (5):244-54.
68. Kimura, M., M. Araie, and S. Koyano. 1996. Movement of carboxyfluorescein across retinal pigment epithelium-choroid. Exp Eye Res 63 (1):51-6.
69. Klein, R., B.E. Klein, S.E. Moss, and K.J. Cruickshanks. 1995. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102 (1):7-16.
70. Koyano, S., M. Araie, and S. Eguchi. 1993. Movement of fluorescein and its glucuronide across retinal pigment epithelium-choroid. Invest Ophthalmol Vis Sci 34 (3):531-8.
71. Kriechbaum, K., F. Prager, W. Geitzenauer, T. Benesch, C. Schütze, C. Simader, and U. Schmidt-Erfurth. 2009. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. Ophthalmology 116 (12):2415-21.
72. Krohn, J., and T. Bertelsen. 1997a. Corrosion casts of the suprachoroidal space and uveo-scleral drainage routes in the human eye. Acta Ophthalmol Scand 75 (1):32-5.
73. Krohn, J., and T. Bertelsen. 1997b. Corrosion casts of the suprachoroidal space and uveo-scleral drainage routes in the pig eye. Acta Ophthalmol Scand 75 (1):28-31.
74. Krohn, J., and T. Bertelsen. 1998. Light microscopy of uveoscleral drainage routes after gela-tine injections into the suprachoroidal space. Acta Ophthalmol Scand 76 (5):521-7.
75. Kuno, N., and S. Fujii. 2010. Biodegradable intraocular therapies for retinal disorders: Progress to date. Drugs Aging 27 (2):117-34.
76. Larsson, B.S. 1993. Interaction between chemicals and melanin. Pigment Cell Res 6 (3):127-33.
77. Leblanc, B., S. Jezequel, T. Davies, G. Hanton, and C. Taradach. 1998. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 28 (2):124-32.
78. Lee, T.W.-Y., and J.R. Robinson. 2004. Drug delivery to the posterior segment of the eye III: The effect of parallel elimination pathway on the vitreous drug level after subconjuncti-val injection. J Ocul Pharmacol Ther 20 (1):55-64.
79. Ling, V. 1992. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer 69 (10):2603-9.
80. Mannermaa, E., K.-S. Vellonen, T. Ryhänen, K. Kokkonen, V.-P. Ranta, K. Kaarniranta, and A. Urtti. 2009. Efflux protein expression in human retinal pigment epithelium cell lines. Pharm Res 26 (7):1785-91.
81. Mannermaa, E., K.-S. Vellonen, and A. Urtti. 2006. Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 58 (11):1136-63.
82. Moore, D.J., and G.M. Clover. 2001. The effect of age on the macromolecular permeability of human Bruch’s membrane. Invest Ophthalmol Vis Sci 42 (12):2970-5.
83. Moore, D.J., A.A. Hussain, and J. Marshall. 1995. Age-related variation in the hydraulic conductivity of Bruch’s membrane. Invest Ophthalmol Vis Sci 36 (7):1290-7.
84. Musch, D.C., D.F. Martin, J.F. Gordon, M.D. Davis, and B.D. Kuppermann. 1997. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 337 (2):83-90.
85. Nelson, M.L., M.T.S. Tennant, A. Sivalingam, C.D. Regillo, J.B. Belmont, and A. Martidis. 2003. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23 (5):686-91.
86. Nicoli, S., G. Ferrari, M. Quarta, C. Macaluso, and P. Santi. 2009. In vitro transscleral iontopho-resis of high molecular weight neutral compounds. Eur J Pharm Sci 36 (4-5):486-92.
87. Nomoto, H., F. Shiraga, N. Kuno, E. Kimura, S. Fujii, K. Shinomiya, A.K. Nugent, K. Hirooka, and T. Baba. 2009. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50 (10):4807-13.
88. Olsen, T.W., S.Y. Aaberg, D.H. Geroski, and H.F. Edelhauser. 1998. Human sclera: Thickness and surface area. Am J Ophthalmol 125 (2):237-41.
89. Olsen, T.W., H.F. Edelhauser, J.I. Lim, and D.H. Geroski. 1995. Human scleral permeabil-ity. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 36 (9):1893-903.
90. Olsen, T.W., X. Feng, K. Wabner, S.R. Conston, D.H. Sierra, D.V. Folden, M.E. Smith, and J.D. Cameron. 2006. Cannulation of the suprachoroidal space: A novel drug delivery methodology to the posterior segment. Am J Ophthalmol 142 (5):777-87.
91. Olsen, T.W., X. Feng, K. Wabner, K. Csaky, S. Pambuccian, and J.D. Cameron. 2011. Pharmacokinetics of pars plana intravitreal injections versus microcannula supracho-roidal injections of bevacizumab in a porcine model. Invest Ophthalmol Vis Sci 52 (7): 4749-56.
92. Olsen, T.W., S. Sanderson, X. Feng, and W.C. Hubbard. 2002. Porcine sclera: Thickness and surface area. Invest Ophthalmol Vis Sci 43 (8):2529-32.
93. Ozkiriş, A., and K. Erkiliç. 2005. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 40 (1):63-8.
94. Parke, D.W. 2003. Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 136 (5):918-9.
95. Patel, S.R., A.S.P. Lin, H.F. Edelhauser, and M.R. Prausnitz. 2010. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 28 (1): 166-76.
96. Pitkänen, L., V.-P. Ranta, H. Moilanen, and A. Urtti. 2005. Permeability of retinal pigment epithelium: Effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci 46 (2):641-6.
97. Rabinovich-Guilatt, L., P. Couvreur, G. Lambert, and C. Dubernet. 2004. Cationic vectors in ocular drug delivery. J Drug Target 12 (9-10):623-33.
98. Ramchandran, R.S., S. Fekrat, S.S. Stinnett, and G.J. Jaffe. 2008. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol 146 (2):285-91.
99. Ramrattan, R.S., T.L. van der Schaft, C.M. Mooy, W.C. de Bruijn, P.G. Mulder, and P.T. de Jong. 1994. Morphometric analysis of Bruch’s membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 35 (6):2857-64.
100. Resnikoff, S., D. Pascolini, D. Etya’ale, I. Kocur, R. Pararajasegaram, G.P. Pokharel, and S.P. Mariotti. 2004. Global data on visual impairment in the year 2002. Bull World Health Organ 82 (11):844-51.
101. Robinson, M.R., S.S. Lee, H. Kim, S. Kim, R.J. Lutz, C. Galban, P.M. Bungay et al. 2006. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcino-lone acetonide. Exp Eye Res 82 (3):479-87.
102. Rogers, S., R.L. McIntosh, N. Cheung, L. Lim, J.J. Wang, P. Mitchell, J.W. Kowalski, H. Nguyen, T.Y. Wong, and International Eye Disease Consortium. 2010. The preva-lence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117 (2):313-9.e1.
103. Rosenfeld, P.J., D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, C.Y. Chung, R.Y. Kim, and MARINA Study Group. 2006. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (14):1419-31.
104. Saha, P., J.J. Yang, and V.H. Lee. 1998. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest Ophthalmol Vis Sci 39 (7):1221-6.
105. Sakai, T., N. Kuno, F. Takamatsu, E. Kimura, H. Kohno, K. Okano, and K. Kitahara. 2007. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats. Invest Ophthalmol Vis Sci 48 (7):3381-7.
106. Salminen, L., G. Imre, and R. Huupponen. 1985. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta Ophthalmol Suppl, 173, 15-8.
107. Scott, I.U., M.S. Ip, P.C. VanVeldhuisen, N.L. Oden, B.A. Blodi, M. Fisher, C.K. Chan et al. 2009. A randomized trial comparing the efficacy and safety of intravitreal triamcino-lone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127 (9):1115-28.
108. Senthilkumari, S., T. Velpandian, N.R. Biswas, A. Bhatnagar, G. Mittal, and S. Ghose. 2009. Evidencing the modulation of P-glycoprotein at blood-ocular barriers using gamma scintigraphy. Curr Eye Res 34 (1):73-7.
109. Shah, S.S., L.V. Denham, J.R. Elison, P.S. Bhattacharjee, C. Clement, T. Huq, and J.M. Hill. 2010. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol 5 (1):75-93.
110. Shirasaki, Y. 2008. Molecular design for enhancement of ocular penetration. J Pharm Sci 97 (7):2462-96.
111. Shuler, R.K., P.K. Dioguardi, C. Henjy, J.M. Nickerson, L.P.J. Cruysberg, and H.F. Edelhauser. 2004. Scleral permeability of a small, single-stranded oligonucleotide. J Ocul Pharmacol Ther 20 (2):159-68.
112. Sieving, P.A., R.C. Caruso, W. Tao, H.R. Coleman, D.J.S. Thompson, K.R. Fullmer, and R.A. Bush. 2006. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 103 (10):3896-901.
113. Singh, S.R., H.E. Grossniklaus, S.J. Kang, H.F. Edelhauser, B.K. Ambati, and U.B. Kompella. 2009. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 16 (5):645-59.
114. Soheilian, M., A. Ramezani, A. Obudi, B. Bijanzadeh, M. Salehipour, M. Yaseri, H. Ahmadieh et al. 2009. Randomized trial of intravitreal bevacizumab alone or combined with triam-cinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116 (6):1142-50.
115. Stahl, A., H. Agostini, L.L. Hansen, and N. Feltgen. 2007. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245 (10):1429-36.
116. Sutter, F.K.P., and M.C. Gillies. 2003. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 87 (8):972-4.
117. Takahashi, K., Y. Saishin, Y. Saishin, A.G. King, R. Levin, and P.A. Campochiaro. 2009. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 127 (4):494-9.
118. Toris, C.B., M.E. Yablonski, Y.L. Wang, and C.B. Camras. 1999. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 127 (4):407-12.
119. Tsuboi, S. 1987. Measurement of the volume flow and hydraulic conductivity across the isolated dog retinal pigment epithelium. Invest Ophthalmol Vis Sci 28 (11):1776-82.
120. Tsuboi, S., T. Fujimoto, Y. Uchihori, K. Emi, S. Iizuka, K. Kishida, and R. Manabe. 1984. Measurement of retinal permeability to sodium fluorescein in vitro. Invest Ophthalmol Vis Sci 25 (10):1146-50.
121. Watsky, M.A., M.M. Jablonski, and H.F. Edelhauser. 1988. Comparison of conjunctival and corneal surface areas in rabbit and human. Curr Eye Res 7 (5):483-6.
122. Yang, J.J., K.J. Kim, and V.H. Lee. 2000. Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharm Res 17 (5):533-8.